Compare ADV & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADV | AUTL |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 596.2M |
| IPO Year | 2019 | 2025 |
| Metric | ADV | AUTL |
|---|---|---|
| Price | $33.09 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $45.83 | $8.50 |
| AVG Volume (30 Days) | 62.6K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,542,642,000.00 | $10,120,000.00 |
| Revenue This Year | $0.63 | $80.32 |
| Revenue Next Year | $0.45 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $0.49 | $1.18 |
| 52 Week High | $47.45 | $2.58 |
| Indicator | ADV | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 41.17 |
| Support Level | $0.70 | $1.37 |
| Resistance Level | $35.50 | $2.07 |
| Average True Range (ATR) | 1.68 | 0.10 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 55.25 | 1.79 |
Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.